Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276973 | 0.87 | HDAC3 (0.35) | KDM4EMRGPRX4MAPTMCL1 | |
| SCHEMBL5725399 | 0.87 | MRGPRX4 (0.41) | KDM4EMRGPRX4MAPTF2MCL1 | |
| SCHEMBL13398705 | 0.87 | HPGD (0.42) | KDM4EMRGPRX4MAPTF2MCL1 | |
| SCHEMBL13398745 | 0.86 | KDM4E (0.34) | KDM4EMRGPRX4MAPTF2MCL1 | |
| SCHEMBL13399037 | 0.84 | HPGD (0.41) | KDM4EMRGPRX4MAPTF2MCL1 | |
| SCHEMBL4947427 | 0.84 | MRGPRX4 (0.40) | KDM4EMRGPRX4MAPTMCL1PDK2 | |
| SCHEMBL13399287 | 0.84 | MAPT (0.35) | KDM4EMRGPRX4MAPTMCL1PDK2 | |
| SCHEMBL5724877 | 0.83 | MRGPRX4 (0.39) | KDM4EMRGPRX4MAPTMCL1PDK2 | |
| SCHEMBL5724880 | 0.82 | PTGER1 (0.38) | KDM4EMRGPRX4MAPTF2CA12 | |
| SCHEMBL5726400 | 0.82 | HPGD (0.39) | KDM4EMRGPRX4MAPTMCL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | KDM4E 2123/4885MRGPRX4 177/4885MAPT 4076/4885 |
| US-20100105905-A1 | EP2 Agonists | PTGER2, PTGER1, PTGIR | KDM4E 2123/4885MRGPRX4 177/4885MAPT 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.